Medtronic study shows economic benefits of continuous glucose monitoring

Medtronic has announced the findings of a new economic analysis that demonstrates the benefits offered by continuous glucose monitoring (CGM) in people with type 2 diabetes.

The study retrospectively analysed real-world data from more than 5,600 people who used professional CGM in the US, highlighting the significant savings that this treatment approach can deliver for healthcare systems.

Over a period of one year after beginning professional continuous glucose monitoring, it was shown that users experienced much lower healthcare costs during a change of a diabetes therapy, such as moving from one diabetes medication to another.

The well-established clinical benefits of professional CGM use in people with type 2 diabetes were also reinforced by the study, which showed that this approach led to blood glucose control improvements.

Laura Stoltenberg, vice-president and general manager of Medtronic's non-intensive diabetes therapies business, said: "These findings suggest that professional continuous glucose monitoring … is not only an important therapy management tool that provides significant clinical benefits, but can also help alleviate the economic burden of type 2 diabetes on the healthcare system."

The company is responsible for developing the iPro2 glucose monitoring system, which provides readings every five minutes for up to six days to provide an accurate and complete picture of glucose fluctuations.

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.